

Nutlin (3)

Catalog No: tcsc0295



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

548472-68-0

Formula:

$C_{30}H_{30}Cl_2N_4O_4$

Pathway:

Apoptosis

Target:

MDM-2/p53

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

581.49


Product Description

Nutlin 3 is a commercial available **p53-MDM2** inhibitor, with **K_i** of 90 nM.

IC50 & Target: Ki: 90 nM (p53-MDM2)^[1]

In Vitro: Nutlin 3 is an inhibitor of the MDM2-p53 interaction. In particular, co-treatment of p53-positive HCT116 cells with 1 μ M of Inauhzin and 2 μ M of Nutlin 3 more significantly activated p53 as measured by its protein level as well as the level of its target p21, PUMA or cleaved PARP as indication of apoptosis^[2]. Nutlin 3 is a small-molecule inhibitor that acts to inhibit MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. As a single agent, Nutlin 3 (2-10 μ M) stabilizes p53 and p21^{WAF} levels and is toxic to WTP53-22RV1 cells (IC₅₀, 4.3 μ M) but has minimal toxicity toward p53-deficient cells (IC₅₀, >10 μ M). Nutlin 3 induces p53 and p21^{WAF} expression in a dose-dependent manner in 22RV1 cells. Short-term cell cycle assays show that, at a dose of 10 μ M, Nutlin 3 increasea slightly the G₁-phase fraction and decreasea S-phase fraction of all three cell lines^[3].

In Vivo: Nutlin 3 can suppress the growth of xenograft tumors derived from human osteosarcoma or leukemia cells, the anti-tumor activity of Nutlin 3 even at the dose of 200 mg/kg per oral administration is marginal in an HCT116-derived xenograft tumor model^[2]. Nutlin 3 may be a useful adjunct to improve the therapeutic ratio using precision radiotherapy targeted to hypoxic cells and warrants further study in vivo^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!